Sayyahfar Shirin, Sadeghian Mahnaz, Amrolalaei Mojgan
Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Department of Pediatrics, School of Medicine, Hazrat-e Ali Asghar Pediatrics Hospital, Iran University of Medical sciences, Tehran, Iran.
Med J Islam Repub Iran. 2021 Jun 28;35:83. doi: 10.47176/mjiri.35.83. eCollection 2021.
Currently, the role of calcium in reducing the duration and severity of diarrhea and its consequences has been considered as a topic of concern. The aim of this study was to evaluate the effect of oral calcium on the duration of acute gastroenteritis in children. This single-blind randomized clinical trial was performed from 2014 to 2016 at Ali Asghar Children's Hospital, Tehran, Iran. Totally, 124 patients (one month to twelve years old) with acute gastroenteritis were enrolled in this study. The patients were divided equally into intervention and placebo groups and received the calcium gluconate 10%, 0.5cc/kg/day and distinct water, respectively. Data analysis was performed using the statistical software SPSS version 20.0 for windows (SPSS Inc., Chicago, IL) and p<0.05 was considered significant. The mean age of the intervention and placebo groups was 26.43±3.74 and 20.84±2.70 months, respectively, and the difference was not significant (p=0.228). The duration of diarrhea in the intervention and placebo groups was 5.27±2.01 and 6.71 ± 2.44 days respectively (p=0.001). In the placebo group, the plasma calcium level was less than 8mg/dl in 1 (1.6%), 8 - 10 mg/dl in 55 (88.7%) and more than 10mg/dl in 6 cases (9. 7%). In the intervention group, there were 7 (11.3%), 55 (88.7%) and 0 (0%) cases in three groups, respectively (p=0.005). The oral calcium gluconate might shorten the duration of acute gastroenteritis. Therefore, it could be considered as an adjunctive therapy. Whether the formulation of the oral rehydration solution (ORS) will be updated in the future with adding the calcium salts remains to be defined and needs more investigations.
目前,钙在缩短腹泻持续时间和减轻腹泻严重程度及其后果方面的作用已成为一个备受关注的话题。本研究的目的是评估口服钙对儿童急性胃肠炎病程的影响。这项单盲随机临床试验于2014年至2016年在伊朗德黑兰的阿里·阿斯加尔儿童医院进行。共有124例年龄在1个月至12岁之间的急性胃肠炎患者纳入本研究。患者被平均分为干预组和安慰剂组,分别接受10%的葡萄糖酸钙,0.5cc/kg/天和清水。使用Windows版统计软件SPSS 20.0(SPSS公司,伊利诺伊州芝加哥)进行数据分析,p<0.05被认为具有统计学意义。干预组和安慰剂组的平均年龄分别为26.43±3.74个月和20.84±2.70个月,差异无统计学意义(p=0.228)。干预组和安慰剂组的腹泻持续时间分别为5.27±2.01天和6.71±2.44天(p=0.001)。在安慰剂组中,血浆钙水平低于8mg/dl的有1例(1.6%),8 - 10mg/dl的有55例(88.7%),高于10mg/dl的有6例(9.7%)。在干预组中,三组分别有7例(11.3%)、55例(88.7%)和0例(0%)(p=0.005)。口服葡萄糖酸钙可能会缩短急性胃肠炎的病程。因此,它可被视为一种辅助治疗方法。未来口服补液盐(ORS)的配方是否会添加钙盐进行更新仍有待确定,需要更多的研究。